Joint (JYNT) Receives a Buy from Maxim Group

By Austin Angelo

In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Joint (JYNTResearch Report), with a price target of $25.00. The company’s shares closed last Monday at $14.85.

According to, Vendetti is a 4-star analyst with an average return of 6.5% and a 46.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ellex Medical Lasers, and Sensus Healthcare.

Currently, the analyst consensus on Joint is a Moderate Buy with an average price target of $25.50, implying a 54.6% upside from current levels. In a report released yesterday, B.Riley FBR also reiterated a Buy rating on the stock with a $26.00 price target.

See today’s analyst top recommended stocks >>

Joint’s market cap is currently $205.9M and has a P/E ratio of 64.23. The company has a Price to Book ratio of 36.04.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.